Gyre is built for biopharma consulting, investment and new company formation.

Promote Trianni's best-in-class human antibody discovery platform. Source technology licensing opportunities and lead associated transactions. Facilitate academic collaborations and proliferation of Trianni technology.

Member of Bay Area BD&L group. Responsibilities include in- and out-licensing of therapeutic assets, initiating and maintaining collaborations with external partners and advising the Merck Research Venture Fund team on selected investment opportunities.

Head of Department of Protein Sciences. Responsible for lead generation and early characterization efforts at Merck supporting indications addressed by Merck's Disease Area franchises. Member of Biologics Review and Licensing Committee and Ambrx Joint Steering Committee.

Head of Department responsible for all large molecule lead discovery and early characterization efforts at Merck. Projects pursued span the full spectrum of indications addressed by Merck's seven Disease Area Franchises.

Head of Biberach NBE Unit. Departmental focus on discovery, design and early development of New Biological Entities. Indications span those across Cardiometabolic, Respiratory, and CNS therapeutic areas.

Protein Biochemistry group leader supervising ten direct and skip-level reports. Group focus on homology modeling/construct design, purification and characterization of mammalian, insect and microbial cell culture-derived antibodies, antigens, enzymes and other research proteins in support of multiple Amgen oncology and inflammation therapeutic area projects. Core project team member on multiple Oncology & Inflammation TA research strategy teams. Seattle site co-leader on early stage biotherapeutic molecule assessment & engineering effort. Advisor to Amgen External R&D Affairs Group and consultant to Amgen Ventures.- Progressed two Amgen antibody-drug conjugate leads to clinical development.- Amgen team leader on antibody-drug conjugate internal technology development project. Set terms and authored contract covering in-licensing from academic lab of novel cytotoxic ADC warheads with initial compound delivery anticipated in Q3-Q4 of 2009. Designed and supervised internal site-specific conjugation project. Presented cost of good manufactured and cost of goods sold comparative analyses to senior Amgen management.- Seattle site team leader on biochemical characterization and optimization efforts supporting novel bi-specific and half-life extension biotherapeutic alternate scaffolds. The modules comprising these alternate modalities are derived via phage library panning, humanized and normal mouse hybridomas, and through rational design strategies.- Core team member on Amgen molecule assessment effort. Supervisory responsibility for initial analysis on commercial potential of antibody therapeutics targeting oncological and inflammatory indications.

Protein Purification group member supervising two direct reports while working full-time at the bench. Responsibility for purification and characterization of mammalian cell culture-derived antibodies, antigens, enzymes and other research proteins in support of multiple Amgen therapeutic area projects. Core team member on key ESA research project with responsibility for providing quarterly project status updates to Amgen executive management.- Derived strategy enabling production of novel, long-acting, phage library-derived erythropoiesis stimulating agents (ESAs) designed to interdict anemia of cancer at ten-fold lower cost of goods manufactured in comparison to conventional production strategies.- AWA team leader on key metabolic disease research project. Derived and championed novel rational design strategy leading to discovery of activity-enhanced, lipid profile-modifying enzyme drug lead with authorship on related patent application.- Introduced modern molecular modeling techniques to the department in support of recombinant protein expression construct design.

Protein expression and purification sub-group leader supervising two to three direct reports. Design and assistance in production of oncology drug-target and other protein expression vectors. Supervision and assistance in production of protein from baculovirus-infected insect cells, yeast, and E. coli for co-crystallization with small-molecule drug leads, HTS, and target validation studies.- Designed expression construct leveraged to produce first known X-ray structure of high-value oncology target.- Derived conditions producing high-resolution co-crystal structures of 11-HSD1 in complex with multiple inhibitor lead series.- Directed and applied novel strategy enabling efficient Se-Met labeling of recombinant protein in insect cell/baculovirus expression system.

(Gryphon was a start-up engaged in chemical synthesis of protein therapeutics including epo and others. Its $100mm deal with Amgen terminated shortly after my departure).Supervision of two direct reports in synthesis and chemical ligation of peptides and polymers into novel, long-acting protein therapeutics homologues. Optimization of synthesis of organic intermediates; chromatography- and mass spectroscopy-based characterization of reaction intermediates and final products. Molecular modeling of biotherapeutic drug leads.

Supervision of two direct reports in gene cloning and expression, purification and characterization of oncology, inflammation and infectious disease drug-target protein. Contribution to development of NMR-based methods and applications. Supervision of and participation in the co-crystallization of protein-ligand complexes and subsequent structural determination.- Established and built-out a fully functional protein production facility as founding employee.- Contributed to development of patented aryl amide series of p38 inhibitors out-licensed to Novartis and currently in phase II clinical trials.

NMR-based characterization of the variable domain of the Herceptin antibody. Expression and characterization of receptor fragments for NMR-based screening of small molecule solid and liquid tumor inhibitors.- Key contributions to multiple proprietary Ab fragment expression and isotopic labeling methods, many of which remain in practice at Genentech.- Multiple contributions to ongoing development efforts in support of Herceptin® and Avastin®.